CompletedNCT04287920
Acamprosate Safe to Use in Individuals With Liver Disease.
Researchers studied Acomprosate, tracking side effects to assess safety in people with alcohol dependence.
Medication studyAges 21+United StatesAddiction
Understand this study
What did researchers investigate?
Researchers studied Acomprosate, tracking side effects to assess safety in people with alcohol dependence.
Who was this study for?
Listed age limits: from 21 years.
- Listed locations
- RochesterSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: September 21, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 12
- Sponsor
- Mayo Clinic
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 21 Years
- Official registry ID
- NCT04287920
- Official title
Show the full official title
A Phase II Study Evaluating the Safety of Acamprosate for Alcohol Use Disorder in Alcohol-related Liver Disease
Get this study by email
Recruitment & locations
CompletedRochester
Questions about this study
What did researchers investigate?
Researchers studied Acomprosate, tracking side effects to assess safety in people with alcohol dependence.
Who is behind this study?
The study sponsor is Mayo Clinic, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Acomprosate.
Who was this study for?
Listed age limits: from 21 years.
